{
  "docId": "019de074-1317-767b-825b-77b5f795fc6c",
  "docSlug": "27adacda91e6c92061c4de59bd9e9dc9",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 44 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 44,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a screenshot of a BMC Neurology paper and a bar chart showing subgroup analysis of OHSA scores.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1317-767b-825b-77b5f795fc6c/8",
  "deckHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c",
  "deckJsonHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c.json",
  "deckAnchorHref": "/decks/019de074-1317-767b-825b-77b5f795fc6c#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.21,
        "y": 0.15
      },
      "kind": "callout",
      "text": "40% of patients with nOH taking pressor agents are still symptomatic",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52453e8e-bb63-4677-a529-15ca89b96694",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.8,
        "y": 0.5
      },
      "kind": "callout",
      "text": "What determines the response to treatment?",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b003e4d5-76b4-4c9e-87b5-3e86a69d6ccf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.44,
        "y": 0.365
      },
      "kind": "chart",
      "text": "Subgroup analysis of Change in OHSA Item 1 Score",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9cdc279-d149-4d7b-b81c-25397b1e0d68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.07,
        "y": 0.365
      },
      "kind": "image",
      "text": "BMC Neurology paper screenshot",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "558e2f55-e71a-42dc-be05-c37d56aeda70",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.35,
        "x": 0.44,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "nOH symptoms did not significantly improve after taking droxidopa in patients with MSA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "324f1993-4fd4-4897-956f-9d9a75f14ab0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.07,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "Clinical trials showed that ~30% of patients taking droxidopa had no increase in blood pressure.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81a88624-478d-4996-a137-f7b236218889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.04,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; OHSA, Orthostatic Hypotension Symptom Assessment.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f90afc5f-891d-4684-8128-e0b18dcf9349",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Still an Unmet Need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e03e271-b986-42b0-9ddf-eafb3d947b96",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "5422c3a4-dda0-4f7a-9416-1e1af3aadbc0",
      "evidence": "Still an Unmet Need",
      "confidence": 0.5
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "99877feb-40f8-4085-be24-1fa7e645d506",
      "evidence": "Clinical trials showed that ~30% of patients taking droxidopa had no increase in blood pressure.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "29ae0a7e-aeb5-49e1-91d1-0a829a543cc3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "c2344040-10ec-4946-8746-a14cdce330db",
      "evidence": "The deck highlights the limitations of current treatments and the worsening of symptoms in patients with nOH.",
      "position": 2,
      "objective": "What are the consequences of not treating nOH effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}